Orchard Therapeutics: A 'Discreet Axing' of Bubble Baby Treatment
Orchard Therapeutics’ abandonment of a highly successful treatment for a rare affliction known as the bubble baby disease has been described by a well-known industry news site as a “discreet” move, but the site also said that stock analysts still have questions.
The assessment came from the online website, Endpoints, in a piece headlined, “Orchard di…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.